{
    "nctId": "NCT02900443",
    "officialTitle": "A Randomised, Open-label Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Naive Autoimmune Hepatitis",
    "inclusionCriteria": "* Probable or definite diagnosis of autoimmune hepatitis according to the International Autoimmune Hepatitis Study Group criteria\n* First presentation of AIH requiring treatment according to the current EASL guidelines\n* Age \u2265 18 years\n* Must provide informed consent and agree to comply with the trial protocol\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "* Overlap syndrome with Primary Sclerosing Cholangitis (PSC) or Primary Biliary Cholangitis (PBC) (Paris criteria, strong positive Anti-Mitochondrial Antibodies (AMA), past liver biopsy or cholangiographic findings compatible with PBC or PSC).\n* Presentation with acute liver failure, defined as presence of hepatic encephalopathy and coagulopathy (INR \\> 1.5)\n* Current treatment with prednisone/prednisolone and/or immunosuppressive medication for an indication other than autoimmune hepatitis\n* Current systemic infection\n* Other clinically significant medical conditions that could interfere with the trial\n* If female of childbearing potential: known pregnancy, or unwilling to practice anticontraceptive measures.\n* History of noncompliance with medical regimens, or patients who are considered to be potentially unreliable or unable to participate\n* Mental instability or incompetence, such that the validity of informed consent or compliance with the trial is uncertain"
}